|
|
L Pascoe, X Jeunemaitre, M C Lebrethon, K M Curnow, C E Gomez-Sanchez, J M Gasc, J M Saez, P Corvol
J Clin Invest. 1995;
96(5):2236
doi:10.1172/JCI118279
Abstract |
Full text
| PDF

G
lucocorticoid-suppressible hyperaldosteronism is a dominantly inherited form of hypertension believed to be caused by the presence of a hybrid CYP11B1/CYP11B2 gene which has arisen from an unequal crossing over between the two CYP11B genes in a previous meiosis. We have studied a French pedigree with seven affected individuals in which two affected individuals also have adrenal tumors and two others have micronodular adrenal hyperplasia. One of the adrenal tumors and the surrounding adrenal tissue has been removed, giving a rare opportunity to study the regulation and action of the hybrid gene causing the disease. The hybrid CYP11B gene was demonstrated to be expressed at higher levels than either CYP11B1 or CYP11B2 in the cortex of the adrenal by RT-PCR and Northern blot analysis. In situ hybridization showed that both CYP11B1 and the hybrid gene were expressed in all three zones of the cortex. In cell culture experiments hybrid gene expression was stimulated by ACTH leading to increased production of aldosterone and the hybrid steroids characteristic of glucocorticoid-suppressible hyperaldosteronism. The genetic basis of the adrenal pathologies in this family is not known but may be related to the duplication causing the hyperaldosteronism.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(37)
| Title and authors |
Publication |
Year |
Inherited forms of mineralocorticoid hypertension
Zaki Hassan-Smith, Paul M Stewart
|
Current Opinion in Endocrinology, Diabetes and Obesity
|
2011 |
Familial or Genetic Primary Aldosteronism and Gordon Syndrome
Michael Stowasser, Eduardo Pimenta, Richard D. Gordon
|
Endocrinology & Metabolism Clinics of North America
|
2011 |
Acute and chronic regulation of aldosterone production
Namita G. Hattangady, Lawrence O. Olala, Wendy B. Bollag, William E. Rainey
|
Molecular and Cellular Endocrinology
|
2011 |
Expression of Genes Encoding Aldosterone Synthesis Pathway Enzymatic Proteins in Adrenocortical Adenomas in Patients With Conn Syndrome
Jacek Ziaja, Krzysztof Cholewa, Jerzy Chudek, Robert Król, Maciej Kajor, Andrzej Więcek, Urszula Mazurek, Lech Cierpka
|
Polish Journal of Surgery
|
2010 |
Regulation of Aldosterone Production
William E. Rainey, Wendy B. Bollag, Carlos M. Isales
|
Textbook of Nephro-Endocrinology
|
2009 |
Clinical and biochemical characteristics of normotensive patients with primary aldosteronism: a comparison with hypertensive cases
Virginie Médeau, François Moreau, Ludovic Trinquart, Maud Clemessy, Jean-Louis Wémeau, Marie Christine Vantyghem, Pierre-François Plouin, Yves Reznik
|
Clinical Endocrinology
|
2008 |
Urinary Aldosterone-to-active-renin Ratio: A Useful Tool for Predicting Resolution of Hypertension After Adrenalectomy in Patients With Aldosterone-producing Adenomas
Jean-Jacques Mourad, Xavier Girerd, Paul Milliez, Marilucy Lopez-Sublet, Sylvain Lejeune, Michel E. Safar
|
Am J Hypertens
|
2008 |
Angiotensin II activates p44/42 MAP kinase partly through PKCɛ in H295R cells
Jean-Guy LeHoux, Andrée Lefebvre
|
Molecular and Cellular Endocrinology
|
2007 |
New concepts in adrenal vein sampling for aldosterone in the diagnosis of primary aldosteronism
Gian Paolo Rossi
|
Current Science Inc
|
2007 |
Genetic Forms of Primary Aldosteronism
Michael Stowasser, Francesco Fallo, Albertina So, Yvette Jeske, Livia Kelemen, Catia Pilon, Richard Gordon
|
High Blood Pressure & Cardiovascular Prevention
|
2007 |
|